BCM
ALDX icon

BlueCrest Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

BlueCrest Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20,000
Closed -$276K – 837
2018
Q3 		$276K Buy
+20,000
New +$162K 0.01% 1081
2018
Q2 		– Sell
-14,371
Closed -$108K – 1458
2018
Q1 		$108K Buy
+14,371
New +$109K ﹤0.01% 1355

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlueCrest Capital Management's ALDX Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2018, closing a stake of 20,000 shares — an estimated $276K sold.

BlueCrest Capital Management first reported a position in ALDX in Q1 2018 and held it in 2 quarters. The position peaked at $276K in Q3 2018. 77 funds tracked by Wall St. Rank hold ALDX as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Aldeyra Therapeutics position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 20,000 Aldeyra Therapeutics shares in Q4 2018, an estimated $276K.
  • BlueCrest Capital Management first reported a position in Aldeyra Therapeutics in Q1 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Aldeyra Therapeutics position peaked at $276K in Q3 2018.
  • 77 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.